Bristol-Myers Squibb Co (NYSE:BMY) has been assigned an average rating of “Hold” from the twenty-three research firms that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $61.95.

Several research firms have recently issued reports on BMY. Societe Generale set a $47.00 price target on Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Wednesday, November 14th. BMO Capital Markets increased their price target on Bristol-Myers Squibb from $55.00 to $58.00 and gave the stock a “market perform” rating in a research note on Friday, November 16th. William Blair reissued an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Tuesday, November 27th. Credit Suisse Group set a $61.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Sunday, October 14th. Finally, Morgan Stanley decreased their price target on Bristol-Myers Squibb from $63.00 to $59.00 and set a “hold” rating for the company in a research note on Tuesday, November 6th.

Several institutional investors have recently made changes to their positions in BMY. Wealth Architects LLC lifted its holdings in shares of Bristol-Myers Squibb by 14.0% during the third quarter. Wealth Architects LLC now owns 6,923 shares of the biopharmaceutical company’s stock valued at $430,000 after purchasing an additional 848 shares during the last quarter. Beech Hill Advisors Inc. lifted its holdings in shares of Bristol-Myers Squibb by 0.8% during the third quarter. Beech Hill Advisors Inc. now owns 105,500 shares of the biopharmaceutical company’s stock valued at $6,549,000 after purchasing an additional 850 shares during the last quarter. Signature Financial Management Inc. lifted its holdings in shares of Bristol-Myers Squibb by 1.9% during the second quarter. Signature Financial Management Inc. now owns 46,006 shares of the biopharmaceutical company’s stock valued at $2,546,000 after purchasing an additional 870 shares during the last quarter. Mcmillion Capital Management Inc. lifted its holdings in shares of Bristol-Myers Squibb by 1.4% during the second quarter. Mcmillion Capital Management Inc. now owns 64,044 shares of the biopharmaceutical company’s stock valued at $3,544,000 after purchasing an additional 903 shares during the last quarter. Finally, Securian Asset Management Inc lifted its holdings in shares of Bristol-Myers Squibb by 0.5% during the second quarter. Securian Asset Management Inc now owns 167,108 shares of the biopharmaceutical company’s stock valued at $9,248,000 after purchasing an additional 912 shares during the last quarter. Institutional investors and hedge funds own 72.74% of the company’s stock.

BMY traded up $1.22 during trading on Thursday, reaching $53.25. 11,210,748 shares of the company were exchanged, compared to its average volume of 7,804,573. The company has a market cap of $84.92 billion, a P/E ratio of 17.69, a PEG ratio of 1.45 and a beta of 1.11. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.53 and a quick ratio of 1.40. Bristol-Myers Squibb has a 52 week low of $46.94 and a 52 week high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.09 EPS for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.18. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. The firm had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. As a group, research analysts anticipate that Bristol-Myers Squibb will post 3.87 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 1st. Stockholders of record on Friday, January 4th will be issued a $0.41 dividend. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. This represents a $1.64 annualized dividend and a dividend yield of 3.08%. Bristol-Myers Squibb’s dividend payout ratio is 53.16%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Featured Article: Return on Investment (ROI) Defined, Explained

Analyst Recommendations for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.